The firm plans to launch testing in the US this fall through Atlanta-based Alpha Genomix, and is looking for similar partners in Asia for a new Asia-specific panel.

The company's test, CNSDose, incorporates multiple genes involved in metabolism of antidepressants in the liver and how they cross into the brain via the blood-brain-barrier.

Originally published May 15.

Diamond Healthcare will initially provide AssureRx Health's GeneSightRx psychiatric pharmacogenetic test in 10 of its behavioral health units, but plans to expand adoption of PGx testing within its 30-state network.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.